Metchnikoff Therapeutics

Metchnikoff Therapeutics is a biotechnology company dedicated to developing innovative treatments for inflammatory and autoimmune diseases by leveraging the human microbiome. Founded in 2015 as a PureTech Health entity, the company was built on the pioneering research of Dr. Ruslan Medzhitov and Dr. Alexander Chervonsky regarding the interplay between commensal microbes and the innate immune system. The company's platform focuses on identifying specific microbial signals that can be harnessed to modulate immune responses and restore homeostasis. Its approach involves the development of live biotherapeutic products (LBPs) and other microbial-derived therapies. In early 2023, Metchnikoff Therapeutics was acquired by AstraZeneca, integrating its specialized microbiome expertise into AstraZeneca's immunology and inflammation R&D portfolio.